Literature DB >> 23861100

Distribution of genital wart human papillomavirus genotypes in China: a multi-center study.

Lihong Chang1, Puwa Ci, Jufang Shi, Kan Zhai, Xiaoli Feng, Danny Colombara, Wei Wang, Youlin Qiao, Wen Chen, Yuping Wu.   

Abstract

Although it is understood that low-risk human papillomavirus (HPV) genotypes are associated with genital warts, there have been very few published studies reporting the genotype-specific prevalence of HPV among Chinese population. The aim of the study was to assess the prevalence of HPV genotypes in genital warts across China, and thus to evaluate the potential benefit of a quadrivalent HPV vaccine in this population. The tissue samples of a total of 1,005 genital warts cases were collected from seven geographical regions of China. HPV genotypes were analyzed using the general primer PCR and sequence-based typing method. Prevalence differences between sexes, geographical regions and age groups were assessed. The overall prevalence of HPV DNA in genital warts patients was 88.7% (891/1,005). Low-risk genotypes predominated, with a prevalence of 78.1% (785/1,005). The most prevalent genotypes were HPV-6 (41.3%), HPV-11 (37.6%) and HPV-16 (10.4%). Among HPV positive patients, single infections were more frequent (866/891, 97.2%) than co-infections (25/891, 2.8%). Both the overall prevalence of HPV DNA and that of HPV-6/-11/-16 (positive for any of the three types) decreased with age (P-trend = 0.010 and P-trend = 0.025, respectively). The prevalence of HPV-6/-11 (positive for either HPV type) and HPV-16 varied by geographic region (P = 0.003 and P ≤ 0.001, respectively). The prevalence of HPV-16 in female patients between urban and rural areas showed a marginally significant difference (P = 0.05). In sum, the results provide strong evidence that, in China, the most prevalent HPV genotypes in genital warts are HPV-6, HPV-11 and HPV-16. This indicates that a quadrivalent HPV vaccine may decrease the incidence of genital warts in the future.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  China; HPV genotypes; distribution; genital warts; human papillomavirus

Mesh:

Year:  2013        PMID: 23861100      PMCID: PMC5463542          DOI: 10.1002/jmv.23646

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  44 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Development of genital warts after incident detection of human papillomavirus infection in young men.

Authors:  Yuzo Arima; Rachel L Winer; Qinghua Feng; James P Hughes; Shu-Kuang Lee; Michael E Stern; Sandra F O'Reilly; Laura A Koutsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

3.  Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.

Authors:  Pierre Vandepapeliere; Renzo Barrasso; Chris J L M Meijer; Jan M M Walboomers; Martine Wettendorff; Lawrence R Stanberry; Charles J N Lacey
Journal:  J Infect Dis       Date:  2005-11-11       Impact factor: 5.226

4.  Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China.

Authors:  Yuping Wu; Yulong Chen; Longyu Li; Guifang Yu; Ying He; Yanling Zhang
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

Review 5.  The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses.

Authors:  Hans-Ulrich Bernard
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

6.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

7.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

Review 8.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

Authors:  F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

9.  Real-time PCR assays using internal controls for quantitation of HPV-16 and beta-globin DNA in cervicovaginal lavages.

Authors:  Jonas Lefevre; Catherine Hankins; Karina Pourreaux; Hélène Voyer; François Coutlée
Journal:  J Virol Methods       Date:  2003-12       Impact factor: 2.014

10.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

View more
  8 in total

1.  Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.

Authors:  Lukai Zhai; Rashi Yadav; Nitesh K Kunda; Dana Anderson; Elizabeth Bruckner; Elliott K Miller; Rupsa Basu; Pavan Muttil; Ebenezer Tumban
Journal:  Antiviral Res       Date:  2019-03-26       Impact factor: 5.970

2.  Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer.

Authors:  Wei Huang; Shuli Zhu; Qiang Liu; Chanyu Li; Li Li
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  Efficacy and Safety of Clinacanthus nutans Lindau Cream vs. Podophyllin for the Treatment of Adults with Condyloma Acuminata.

Authors:  Sukhum Jiamton; Pattriya Chanyachailert; Yanisorn Nanchaipruek; Nuttagarn Jantanapornchai; Poramin Patthamalai; Pichaya Limphoka; Ya-Nin Nokdhes; Jiraporn Jantaravinid
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-23       Impact factor: 2.650

4.  Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study.

Authors:  Cansheng Zhu; Yaofei Wang; Weihua Mao; Hongshan Zhang; Jiaju Ma
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

5.  Determinants of high-risk human papillomavirus infection in anogenital warts.

Authors:  Goknur Ozaydin-Yavuz; Serap Gunes Bilgili; Huseyin Guducuoglu; Ibrahim Halil Yavuz; Sema Elibuyuk-Aksac; Ayse Serap Karadag
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

6.  Investigation of frequency and typing of human papillomavirus among genital warts using a reverse dot blot hybridization approach.

Authors:  Majid Zare-Bidaki; Mahmoud Zardast; Ali Nadjafi-Semnani; Mohammad Nadjafi-Semnani; Davod Javanmard; Shokouh Ghafari; Nahid Ghanbarzadeh
Journal:  BMC Infect Dis       Date:  2022-03-22       Impact factor: 3.090

7.  Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.

Authors:  Rashi Yadav; Lukai Zhai; Nitesh K Kunda; Pavan Muttil; Ebenezer Tumban
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

Review 8.  Sustained high prevalence of viral hepatitis and sexually transmissible infections among female sex workers in China: a systematic review and meta-analysis.

Authors:  Shu Su; Eric P F Chow; Kathryn E Muessig; Lei Yuan; Joseph D Tucker; Xiaohu Zhang; Jiehui Ren; Christopher K Fairley; Jun Jing; Lei Zhang
Journal:  BMC Infect Dis       Date:  2016-01-05       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.